Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria.

Röth A, Nishimura JI, Nagy Z, Gaàl-Weisinger J, Panse J, Yoon SS, Egyed M, Ichikawa S, Ito Y, Kim JS, Ninomiya H, Schrezenmeier H, Sica S, Usuki K, Sicre de Fontbrune F, Soret J, Sostelly A, Higginson J, Dieckmann A, Gentile B, Anzures-Cabrera J, Shinomiya K, Jordan G, Biedzka-Sarek M, Klughammer B, Jahreis A, Bucher C, Peffault de Latour R.

Blood. 2020 Mar 19;135(12):912-920. doi: 10.1182/blood.2019003399.

2.

Calreticulin mutation specific CAL2 immunohistochemistry accurately identifies rare calreticulin mutations in myeloproliferative neoplasms.

Mózes R, Gángó A, Sulák A, Vida L, Reiniger L, Timár B, Krenács T, Alizadeh H, Masszi T, Gaál-Weisinger J, Demeter J, Csomor J, Matolcsy A, Kajtár B, Bödör C.

Pathology. 2019 Apr;51(3):301-307. doi: 10.1016/j.pathol.2018.11.007. Epub 2018 Dec 31.

PMID:
30606612
3.

[Novelties and experience with tyrosine kinase inhibitor therapy in chronic myeloid leukemia].

Gaál-Weisinger J, Mucsi O, Körösmezey G, Szili B, Eid H, Kiss R, Bödör C, Tárkányi I, Nagy Z, Demeter J.

Magy Onkol. 2017 Mar 8;61(1):67-74. Epub 2017 Feb 3. Review. Hungarian.

4.

[Molecular monitoring of myeloid leukemia].

Kiss R, Király AP, Gaál-Weisinger J, Marosvári D, Gángó PA, Demeter J, Bödör C.

Magy Onkol. 2017 Mar 8;61(1):57-66. Epub 2017 Jan 29. Review. Hungarian.

Supplemental Content

Loading ...
Support Center